The Amyris Inc. (AMRS) Raised to Hold at Zacks Investment Research

The Amyris Inc. (AMRS) Raised to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of Amyris Inc. (NASDAQ:AMRS) from a sell rating to a hold rating in a research report sent to investors on Monday.

According to Zacks, “Amyris INC is an integrated renewable products company applying industrial synthetic biology to genetically modify microorganisms to serve as living factories. Amyris designs these microorganisms to produce defined molecules for use as renewable chemicals and transportation fuels. The Company is engaged in the development of farmesene- a molecule, which serves as the base chemical building block for a wide range of renewable products to replace existing products that are derived from petroleum, plant or animal sources and that may be of lower quality or higher price. Amyris INC is headquartered in Emeryville, CA. “

A number of other brokerages have also recently issued reports on AMRS. HC Wainwright set a $4.00 target price on Amyris and gave the stock a buy rating in a research report on Tuesday, January 10th. Singular Research reaffirmed a buy rating and set a $2.80 target price on shares of Amyris in a research report on Wednesday, September 28th. Finally, Rodman & Renshaw reaffirmed a buy rating and set a $4.00 target price on shares of Amyris in a research report on Wednesday, January 11th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock has a consensus rating of Buy and a consensus target price of $2.66.

Shares of Amyris (NASDAQ:AMRS) opened at 0.6748 on Monday. The firm’s 50-day moving average is $0.76 and its 200 day moving average is $0.63. Amyris has a 1-year low of $0.31 and a 1-year high of $1.63. The company’s market cap is $177.48 million.

Amyris (NASDAQ:AMRS) last announced its earnings results on Wednesday, November 2nd. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by $0.01. The business earned $26.50 million during the quarter, compared to analysts’ expectations of $33.61 million. The firm’s revenue for the quarter was up 208.1% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.23) earnings per share. Equities analysts expect that Amyris will post ($0.25) EPS for the current fiscal year.

In other news, major shareholder (Mauritius) Pte Ltd Maxwell sold 2,611,233 shares of the stock in a transaction that occurred on Friday, November 4th. The stock was sold at an average price of $0.89, for a total value of $2,323,997.37. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 48.70% of the stock is owned by insiders.

A hedge fund recently raised its stake in Amyris stock. KBC Group NV boosted its position in shares of Amyris Inc. (NASDAQ:AMRS) by 330.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 329,101 shares of the company’s stock after buying an additional 252,589 shares during the period. KBC Group NV owned approximately 0.14% of Amyris worth $191,000 at the end of the most recent reporting period. Institutional investors own 30.40% of the company’s stock.

About Amyris

Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.

Get a free copy of the Zacks research report on Amyris (AMRS)

For more information about research offerings from Zacks Investment Research, visit

Related posts

Leave a Comment